These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24503027)

  • 1. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
    Jehn CF; Böning L; Kröning H; Pezzutto A; Lüftner D
    Eur J Cancer; 2014 May; 50(7):1269-75. PubMed ID: 24503027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
    Carneiro BA; Ramanathan RK; Fakih MG; Krishnamurthi SS; Lembersky BC; Stoller RG; Lancaster SL; Pinkerton RA; Crandall TL; Schmotzer AR; Potter DM; Bahary N
    Clin Colorectal Cancer; 2012 Mar; 11(1):53-9. PubMed ID: 21813336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
    Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
    Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
    Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
    Buzaid AC; Mathias Cde C; Perazzo F; Simon SD; Fein L; Hidalgo J; Murad AM; Esser R; Senger S; Lerzo G
    Clin Colorectal Cancer; 2010 Dec; 9(5):282-9. PubMed ID: 21208842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
    Shitara K; Ura T; Matsuo K; Takahari D; Yokota T; Yuki S; Yoshida M; Utsunomiya S; Sato Y; Yamaura H; Kato M; Inaba Y; Tajika M; Kawai H; Yamazaki K; Komatsu Y; Muro K
    Eur J Cancer; 2011 Dec; 47(18):2673-80. PubMed ID: 21652203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
    Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
    Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
    J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
    Gamucci T; Nelli F; Cianci G; Grassi G; Moscetti L; Sperduti I; Zeuli M; Cortesi E; D'Auria G; Pollera CF
    Clin Colorectal Cancer; 2008 Jul; 7(4):273-9. PubMed ID: 18650196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].
    Nēmecek R; Kocáková I; Kocák I; Svoboda M; Lakomý R; Poprach A; Vyskocil J; Vyzula R
    Klin Onkol; 2009; 22(1):27-33. PubMed ID: 19534437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
    Wilke H; Glynne-Jones R; Thaler J; Adenis A; Preusser P; Aguilar EA; Aapro MS; Esser R; Loos AH; Siena S
    J Clin Oncol; 2008 Nov; 26(33):5335-43. PubMed ID: 18854570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.